Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

VRN11

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Voronoi

Drug class:

EGFR inhibitor

Related drugs:

‹

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

›

EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	VRN11 Sensitive: D – Preclinical VRN11 Sensitive : D	VRN11 Sensitive: D – Preclinical VRN11 Sensitive : D
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	VRN11 Sensitive: D – Preclinical VRN11 Sensitive : D	VRN11 Sensitive: D – Preclinical VRN11 Sensitive : D
EGFR L858R + EGFR C797S	Non Small Cell Lung Cancer	EGFR L858R + EGFR C797S	Non Small Cell Lung Cancer	VRN11 Sensitive: D – Preclinical VRN11 Sensitive : D	VRN11 Sensitive: D – Preclinical VRN11 Sensitive : D
EGFR exon 19 deletion + EGFR C797S	Non Small Cell Lung Cancer	EGFR exon 19 deletion + EGFR C797S	Non Small Cell Lung Cancer	VRN11 Sensitive: D – Preclinical VRN11 Sensitive : D	VRN11 Sensitive: D – Preclinical VRN11 Sensitive : D